|Title:||Parenteral formulation for epothilone analogs|
|Abstract:|| A process for formulating certain epothilone analogs for parenteral administration is disclosed wherein the analog is dissolved in a mixture of at least 50% by volume tertiary-butanol in water, the mixture is lyophilized, the resulting lyophilized product is packaged in one vial with a sufficient amount of solvent comprising anhydrous ethanol and a suitable nonionic surfactant in a second vial. All steps are carried out with protection from light. In use, the contents of the second or diluent vial are added to the lyophilized product and mixed to constitute the epothilone analog and the resulting solution is diluted with a suitable diluent to produce a solution for intravenous injection containing the epothilone analog in a concentration of from about 0.1 mg/mL to about 0.9 mg/mL. A preferred surfactant is polyethoxylated castor oil and a preferred diluent is Lactated Ringer's Injection.|
|Inventor(s):|| Bandyopadhyay; Rebanta (Portage, MI), Malloy; Timothy M. (Yardley, PA), Panaggio; Andrea (West Windsor, NJ), Raghavan; Krishnaswamy Srinivas (Cranbury, NJ), Varia; Sailesh Amilal (Princeton Junction, NJ) |
|Assignee:|| Bristol-Myers Squibb Company (Princeton, NJ) |
|Filing Date:||Nov 04, 2008|
|Claims:||1. A process for lyophilizing an epothilone analog comprising dissolving an epothilone analog having the formula, ##STR00007## in a solvent mixture comprising tertiary-butanol and water to form an epothilone analog solution and then drying the epothilone analog solution under vacuum to provide the lyophilized epothilone analog. |
2. A lyophilized epothilone analog prepared according to the process of claim 1.
3. A pharmaceutical product comprising at least a first and a second vial wherein the first vial contains a lyophilized epothilone analog prepared according to claim 1, and the second vial contains a sufficient quantity of a solution to effect reconstitution of the lyophilized epothilone analog.